CROI 2017 Program and Information

Program and Agenda

425 PHARMACOKINETICS, SAFETY, AND EFFICACY OF ATV OR DRV WITH COBI IN ADOLESCENTS Elizabeth J. McFarland 1 , Gloria P. Heresi 2 , Jag Batra 3 , Torsak Bunupuradah 4 , Kulkanya Chokephaibulkit 5 , Pope Kosalarksa 6 , Pamela Wong 7 , Heather Zhang 7 , Cheryl Pikora 7 , Martin Rhee 7 1 Univ of Colorado, Aurora, CO, USA, 2 Univ of Texas, Houston, TX, USA, 3 Miller Children’s Hosp, Long Beach, CA, USA, 4 HIV-NAT,Thai Red Cross AIDS Rsr, Bangkok, Thailand, 5 Mahidol Univ, Bangkok, Thailand, 6 Khon Kaen Univ, Khon Kaen, Thailand, 7 Gilead Scis, Inc, Foster City, CA, USA 426 EFFECT OF DOLUTEGRAVIR PLASMA CONCENTRATION ON CENTRAL NERVOUS SYSTEMSIDE EFFECTS Hiroki Yagura 1 , Dai Watanabe 1 , Takao Nakauchi 1 , Kosuke Tomishima 1 , Daisuke Kasai 1 , Yasuharu Nishida 1 , Munehiro Yoshino 2 , Tomoko Uehira 1 , Kunio Yamazaki 1 , Takuma Shirasaka 1 1 Natl Hosp, Osaka, Japan, 2 Natl Hosp Org Osaka Minami Med Cntr, Osaka, Japan 427 EVALUATION OF RPV/FTC/TAF EXPOSURE-EFFICACY AND EXPOSURE-SAFETY RELATIONSHIPS Sophia R. Majeed 1 , Kavitha Bhasi 1 , Yongwu Shao 1 , William Garner 1 , Jenna Scott 1 , Carlos P. Ruixo 2 , Devi SenGupta 1 , Huyen Cao 1 , Brian P. Kearney 1 , Joseph M. Custodio 1 1 Gilead Scis, Foster City, CA, USA, 2 Janssen Rsr and Development, Beerse, Belgium Poster P-H1 I WANT A NEW DRUG Poster Hall - 4 EF 2:30 PM - 4:00 PM 433 NOVEL HIV PI WITHHIGH RESISTANCE BARRIER AND POTENTIAL FOR UNBOOSTED QD ORAL DOSING John O. Link , Darryl Kato, Michael Moore, AndrewMulato, Bernard Murray, Judy Mwangi, Nathan D. Shapiro, George Stepan, Yujin Wang, Zheng-Yu Yang Gilead Scis, Inc, Foster City, CA, USA 434 NOVEL NON-CATALYTIC SITE INTEGRASE INHIBITORWITH IMPROVED RESISTANCE PROFILE Michael L. Mitchell , Mini Balakrishnan, Gediminas Brizgys, Ruby Cai, Eric Lansdon, Andrew Mulato, Mark Osier, Jianhong Wang, Helen Yu, Roman Sakowicz Gilead Scis, Inc, Foster City, CA, USA 435 MK-8591 CONCENTRATIONS AT SITES OF HIV TRANSMISSION AND REPLICATION Jay Grobler , Carolyn McHale, Carol Freddo, Dan Dreyer, Li Sun, Marissa Vavrek, Sheila Breidinger, Kerry Fillgrove, Daria Hazuda, Ming-Tain Lai Merck & Co, Inc, West Point, PA, USA 436 GS-9131 IS A NOVEL NRTI WITH ACTIVITY AGAINST NRTI- RESISTANT HIV-1 Kirsten L. White , Nicolas Margot, Kirsten Stray, Helen Yu, George Stepan, Constantine Boojamra, Richard Mackman, Adrian Ray, Michael D. Miller, Tomas Cihlar Gilead Scis, Inc, Foster City, CA, USA

Poster Sessions • Wednesday

CROI 2017 135